Physician profile
Jill B Gaoghagan
NPI 1760555759
$1,572.07
in general payments reported to CMS, 2019-2025
19 companies · $369 in 2025
The $369 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $32.85 · 2021: $54.28 · 2022: $125 · 2023: $319 · 2024: $541 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,228.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $317.02 | 2019-2025 | Bexsero |
| Ironshore Pharmaceuticals INC. | $190.64 | 2023-2024 | Jornay Pm |
| Corium, LLC | $184.18 | 2023-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $154.40 | 2021-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Cranial Technologies, INC | $116.97 | 2020-2025 | Doc Band |
| Sanofi Pasteur INC. | $95.71 | 2020-2024 | |
| Collegium Pharmaceutical, INC. | $66.51 | 2025 | Jornay Pm |
| Abbott Laboratories | $54.31 | 2025 | Id Now Instrument |
| Vertical Pharmaceuticals, LLC | $50.65 | 2024 | Relexxii |
| Verrica Pharmaceuticals INC. | $50.29 | 2023-2025 | Ycanth |
| Alk-Abello, INC | $45.26 | 2025 | Neffy |
| Sobi, INC | $36.80 | 2019-2023 | |
| Phadia US INC. | $35.31 | 2022-2023 | Immunocap |
| Sanofi-Aventis U.S. LLC | $35.18 | 2024 | |
| Tris Pharma INC | $34.55 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $33.04 | 2022-2024 | Flucelvax |
| Kowa Pharmaceuticals America, INC. | $32.58 | 2025 | Zoryve |
| Astrazeneca Pharmaceuticals LP | $24.36 | 2024 | Flumist Quadrivalent |
| Pfizer INC. | $14.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Gaoghagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.